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Reply to Commentary on "Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus"
Modern Pathology (2016) 29, 90-91; doi:10.1038 /modpathol.2015 To the editor: We appreciate the comments by Iwasaki et al regarding our recent article, 'Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus.' They report findings in an independent cohort of cytokeratin 20-negative Merkel cell carcinomas (MCCs), the majority of which are negative for Merkel cell polyomavirus (MCPyV), in agreement with our observations. Among MCCs classified as MCPyV positive in our study, one case (#13) had relatively low MCPyV by quantitative PCR (qPCR). Although qPCR is accepted as the gold standard for MCPyV detection in MCC, there is debate about whether low levels of MCPyV represent tumorigenic virus or contamination by background wild-type virus. [1] [2] [3] In addition, the sensitivity of any given primer pair may vary dramatically from case to case. 1 Hence, currently there is no universally accepted threshold for considering a tumor MCPyV positive by qPCR. We agree with Iwasaki et al that immunohistochemistry for MCPyV large T antigen (LTAg), while less sensitive than qPCR, may be informative in some cases that are borderline by qPCR. We performed immunohistochemistry for LTAg expression in case #13 using CM2B4 antibody as previously described. 4 This demonstrated moderate to strong nuclear staining for LTAg in 480% of tumor cells, validating our classification of this tumor as MCPyV positive.
We agree that loss of cytokeratin-20 expression may be associated with loss of differentiation in MCC. However, further study is needed to determine the molecular similarity of these tumors to conventional (cytokeratin 20-positive) MCC. To the editor: We read with interest the recent study by Massi et al 1 concerning the evaluation of the new anti-human N-Ras (Q61R) monoclonal antibody (clone SP174) in the mutational screening of melanoma samples. As the recently described BRAFV600E mutation-specific immunohistochemistry, an anti-NRASQ61R mutation-specific antibody may consist of a cost-effective and faster ancillary tool in the mutational screening process that has now become a major requirement for the management of patients with metastatic melanoma. The sensitivity and specificity of 100% reported in this study are very encouraging although they need to be confirmed by additional studies as mentioned by the authors, especially in metastatic samples. In our opinion, some other technical points are worth to be notified. First, we want to point out the importance of the characteristics of melanoma samples. The authors have only selected primary melanomas with Breslow thickness over 4 mm, although many melanomas have a far thinner Breslow thickness. No data is provided concerning the percentage of tumoral cells in the samples or the modalities of DNA extraction from formalin-fixed and paraffin-embedded tissues used for molecular genetic analysis. Notably, the use of macro-or micro-dissection based on histopathological examination of hematoxylin and eosin-stained sections is not mentioned. The percentage of tumoral cells in the samples and the mutated allele proportion in the extracted DNA can highly influence the results of molecular analysis and the ability of the genotyping method to detect a mutation. In our opinion, these parameters have to be taken into account when interpreting a molecular mutational status result. 2 If we keep in mind the thicknesses over 4 mm of the melanomas analyzed in this study, we can postulate that all samples contained a great proportion of tumoral cells. Nevertheless, we cannot rule out the hypothesis that a high amount of inflammatory reactive cells in some samples can decrease the relative amount of tumor in the extracted DNA. Another major interest of mutation-specific immunohistochemistry is the ability to stain a minority of tumoral cells within a sample containing a majority of nontumoral cells (ie, thin primary melanoma or lymph node micrometastasis). 3 These data are relevant for diagnosis and could explain that one sample in the study by Massi et al that was initially considered as NRAS wild type by molecular analysis was indeed positive for anti-NRASQ61R immunolabeling and finally found to be NRAS Q61R mutated after molecular reanalysis.
Second, the authors analyzed 97 samples as the last sample of their series was excluded because of amplification failure preventing molecular analysis. In our experience, another advantage of mutationspecific antibodies is the opportunity of bringing out a mutated protein in samples that are not conclusive using genotyping methods (about 2-3% of samples in our experience, unpublished data). The immunohistochemical analysis of this remaining sample could have been of interest, despite the fact that, in case of negativity, an NRAS mutation could not have been definitively ruled out.
Third, the authors defined the cutoff for positivity at 60% or more of viable tumoral cells with moderate to strong immunelabeling intensity. Weaker labeling and/or single interspersed immunostained cells were considered as negative and nonspecific. This fact points out the real difficulty in identifying melanoma cells versus histiocytic/macrophagic cells. We agree with Massi et al that the interpretation of isolated NRASQ61R-or BRAFV600E-immunolabeled cells can be difficult, and sometimes not conclusive especially in case of florid reactive inflammatory infiltrate. Nevertheless, it is still not perfectly clear whether
